<body><script type="text/javascript"> function setAttributeOnload(object, attribute, val) { if(window.addEventListener) { window.addEventListener('load', function(){ object[attribute] = val; }, false); } else { window.attachEvent('onload', function(){ object[attribute] = val; }); } } </script> <div id="navbar-iframe-container"></div> <script type="text/javascript" src="https://apis.google.com/js/platform.js"></script> <script type="text/javascript"> gapi.load("gapi.iframes:gapi.iframes.style.bubble", function() { if (gapi.iframes && gapi.iframes.getContext) { gapi.iframes.getContext().openChild({ url: 'https://www.blogger.com/navbar/14319979?origin\x3dhttp://seriesacompanies.blogspot.com', where: document.getElementById("navbar-iframe-container"), id: "navbar-iframe", messageHandlersFilter: gapi.iframes.CROSS_ORIGIN_IFRAMES_FILTER, messageHandlers: { 'blogger-ping': function() {} } }); } }); </script>

Monday, December 10, 2007

Nanodisc: Drug Development and Delivery


A finalist in the Venture Showcase Nanodisc, Inc. was presented by President and CEO Michael Artinger, Ph.D. Nanodiscs permit the functional solubilization of membrane-associated proteins as both drug targets and as drugs themselves. The proper packaging of membrane-associated proteins in Nanodiscs may result in better functionality of this class of protein-based drugs through improved folding, affinity, stability and reduced toxicity.

The primary focus of the Company is the development and commercialization of Nanodiscs as a delivery platform. Potential payloads include:
  • Membrane-associated proteins such as receptors
  • Small molecules (especially difficult to solubilize drugs)
  • Imaging agents
  • Nucleic acids (such as RNAi)
So what exactly is a Nanodisc? It is a proprietary nano-scale structure created using a process of self-assembly of a phospholipid bilayer disc surrounded by a patented, engineered membrane scaffold protein belt. Both the size and the chemical nature of Nanodiscs can be easily modified. Nanodiscs render amphipathic and hydrophobic molecules easily soluble, offering transformative innovations across a broad range of commercial applications in both in vivo delivery of therapeutics as well as for in vitro drug discovery. The potential of this technology has been demonstrated using a diverse assortment of molecular targets, therapeutic molecules and diagnostic agents.


Management has assembled a unique, proprietary Nanodisc platform for delivery, imaging, diagnostics, target discovery and validation, lead generation and optimization and is pursuing multiple high-value drug and vaccine delivery applications characterized by substantial unmet need and market opportunity with clinical entry of a first candidate anticipated in 2009 while continuing alliance development with "best-in-class" partners to advance their discovery assets. Early funding was secured through IllinoisVENTURES and the Illinois Emerging Technology Fund

If you enjoyed this post get free email updates (here).

0 Comments:

Post a Comment

<< Home